Bavtavirine
- Generic Name
- Bavtavirine
Study of Novel Antiretrovirals in Participants With HIV-1
Phase 1
Completed
- Conditions
- HIV-1-infection
- Interventions
- Drug: B/F/TAFDrug: Standard of Care (Substudy 01)Drug: Standard of Care (Substudy 02)Drug: Standard of Care (Substudy 03)
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 49
- Registration Number
- NCT05585307
- Locations
- 🇺🇸
Washington Health Institute,Substudy-02, Washington, District of Columbia, United States
🇺🇸Washington Health Institute,Substudy-01, Washington, District of Columbia, United States
🇺🇸Washington Health Institute,Substudy-03, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath